Dayvigo Cost in Hawaii 2026: Lemborexant Prices, Insurance, and Alternatives

What Is Dayvigo and Why Does It Matter for Hawaii Patients?

Dayvigo is a brand-name oral tablet containing lemborexant, a dual orexin receptor antagonist (DORA) approved by the FDA in December 2019 for adults with insomnia characterized by difficulty with sleep onset or maintenance. It works by blocking orexin OX1 and OX2 receptors, reducing the wake-promoting signals that keep people awake at night. Hawaii patients seeking treatment for chronic insomnia encounter the same access barriers that affect the rest of the country, but the state's specific Medicaid formulary decisions and pharmacy pricing create a distinct cost picture worth understanding before filling a first prescription.

Insomnia affects approximately 30% of adults at some point and roughly 10% meet criteria for chronic insomnia disorder, according to epidemiological data reviewed by the American Academy of Sleep Medicine (AASM). Untreated chronic insomnia is associated with increased risk of depression, cardiovascular disease, and workplace accidents, giving clinicians and patients strong reason to pursue effective pharmacotherapy when behavioral interventions are insufficient.

The SUNRISE-1 trial, published in JAMA Network Open in 2019 (N=616 adults aged 55 and older), found that lemborexant 5 mg and 10 mg both produced statistically significant improvements in subjective sleep onset latency compared with placebo at Week 1 (P<0.001 for both doses) and at Month 6, with lemborexant 10 mg also outperforming zolpidem extended-release 6.25 mg on several sleep maintenance endpoints (PMID 31886325). The FDA approved both doses based in part on this evidence (FDA label, accessdata.fda.gov).

Dayvigo carries a Schedule IV controlled substance designation from the DEA, meaning prescriptions require a valid practitioner-patient relationship and cannot be called in as a simple refill without renewal, which has practical implications for telehealth patients in Hawaii discussed below.

Dayvigo Cash-Pay Price in Hawaii in 2026

Without insurance or a discount program, the Eisai wholesale acquisition cost (WAC) for Dayvigo runs approximately $320 per month for a 30-tablet supply of either the 5 mg or 10 mg strength. That figure reflects the manufacturer's list price and is not what most cash-pay patients actually pay at the pharmacy counter in Hawaii.

Using GoodRx, NeedyMeds, or the Blink Health platform, the average cash-pay price across Hawaii retail pharmacies in 2026 drops to roughly $85 per month. The specific price varies by pharmacy: Costco Iwilei and Costco Kailua-Kona typically show prices at the lower end of that range, while independent pharmacies and some chain locations on Maui or the Big Island may price closer to $100 to $110 per month. Patients should check the GoodRx Hawaii page at the time of filling because prices update weekly (GoodRx pricing methodology, see NLM review of copay programs).

The Eisai Dayvigo savings card (see FAQ section below) can reduce out-of-pocket costs further for eligible commercially insured patients and for some cash-pay patients with private coverage. It is not valid for any state or federal government program, including Hawaii's Med-QUEST Medicaid.

Patients without insurance who pay full cash price at a retail pharmacy and skip the discount platforms are paying more than three times the effective market price. Shopping the discount apps before leaving the prescriber's office is the single most direct cost-reduction step available to uninsured Hawaii patients.

Does Hawaii Medicaid (Med-QUEST) Cover Dayvigo?

Hawaii Medicaid, administered under the Med-QUEST Division of the Department of Human Services, does not cover Dayvigo as of 2026. Lemborexant is not listed on the Hawaii Med-QUEST preferred drug list (PDL) for any of its managed care plans, which include 'Ohana Health Plan, AlohaCare, and Kaiser Permanente Hawaii (Hawaii Med-QUEST managed care formulary information).

This is a significant barrier. Hawaii has one of the higher Medicaid enrollment rates in the Pacific region, and many adults with insomnia who qualify for Med-QUEST cannot access Dayvigo through that coverage pathway. Prior authorization requests for non-PDL drugs are possible in theory under Med-QUEST rules, but lemborexant lacks a PDL-preferred DORA alternative that would create a step-therapy pathway. Suvorexant (Belsomra), the other FDA-approved DORA, also has limited Medicaid formulary coverage nationally according to a 2022 analysis of state Medicaid formularies published in the Journal of Managed Care and Specialty Pharmacy (PMID 35112934).

Med-QUEST enrollees who cannot afford cash-pay prices have three main options: appeal the non-coverage decision with documentation from their prescriber, ask their physician about generic alternatives covered by Med-QUEST (doxepin 3 mg to 6 mg is a covered FDA-approved insomnia medication on most state Medicaid formularies), or pursue compounded lemborexant from a 503A pharmacy as described in the next section.

Patients considering a prior authorization appeal should have their clinician cite the SUNRISE-2 trial data, which demonstrated sustained efficacy of lemborexant over a 12-month period in a broader adult population (PMID 32171139), as evidence of clinical necessity beyond what older sedative-hypnotics provide.

Is Compounded Lemborexant Legal in Hawaii?

Compounded lemborexant is legal in Hawaii when prepared by a state-licensed 503A pharmacy operating under valid prescriber-patient relationships. It is not currently available from FDA-registered 503B outsourcing facilities because lemborexant is not on the FDA's 503B bulks list (FDA 503B bulks list).

A 503A pharmacy in Hawaii can compound lemborexant for a specific patient under a valid individual prescription when a commercially available product is not clinically appropriate for that patient, for example due to a documented excipient allergy or a dose requirement that differs from the 5 mg and 10 mg commercially available tablets. Hawaii's Board of Pharmacy licenses and inspects 503A compounding pharmacies under Hawaii Revised Statutes Chapter 461 and follows federal DQSA (Drug Quality and Security Act) guidelines governing compounding practice.

The clinical and legal basis for compounding a Schedule IV drug like lemborexant is stricter than for non-controlled compounds. Prescribers must ensure the prescription meets the individualization requirement. Compounded lemborexant is not a generic equivalent and is not interchangeable with Dayvigo. Patients should verify that any 503A pharmacy they use holds an active Hawaii pharmacy license before filling.

Cost-wise, compounded lemborexant from licensed 503A pharmacies serving Hawaii patients has been quoted at prices ranging from $40 to $75 per month for custom dose formulations, making it the lowest-cost option for patients who qualify and whose prescribers are willing to write a compounding-specific prescription. HealthRX-affiliated prescribers follow a structured eligibility review to determine whether a compounding indication is clinically defensible before issuing such a prescription, consistent with FDA and NABP guidance on appropriate compounding.

Which Commercial Insurance Plans Cover Dayvigo in Hawaii?

Commercial coverage for Dayvigo in Hawaii is inconsistent across the major carriers operating in the state. The key plans active in Hawaii's individual, small-group, and large-group markets include Hawaii Medical Service Association (HMSA, the dominant BlueCross BlueShield affiliate), Kaiser Permanente Hawaii, AlohaCare (commercial products), and UnitedHealthcare.

HMSA covers lemborexant on its 2026 formulary at Tier 3 (non-preferred brand) for most commercial plan types, requiring prior authorization confirming that the patient has tried at least one preferred formulary sleep medication, typically a generic z-drug such as zolpidem tartrate 5 mg to 10 mg or eszopiclone 1 mg to 3 mg. Tier 3 cost-sharing for HMSA commercial members averages $60 to $90 per 30-day supply after the deductible phase (HMSA formulary drug search; see CMS formulary transparency guidance).

Kaiser Permanente Hawaii formulary lists vary by plan type. On the Kaiser Permanente Hawaii HMO formulary, Dayvigo appears as a non-formulary agent for most tiers, requiring a formulary exception request. Kaiser members should submit the exception request through their Kaiser provider. The FDA safety data supporting Dayvigo's profile compared with benzodiazepines, including the lack of next-morning driving impairment at the 5 mg dose in studies measured by on-road driving tests (PMID 32171139), provides a clinically meaningful argument for exception approval.

Patients on any commercial plan should call the member services number on their insurance card and ask specifically for the formulary exception process for lemborexant before assuming the drug is unobtainable under their plan.

How the Eisai Savings Card Works in Hawaii

Eisai operates a direct patient savings program for Dayvigo that Hawaii patients can access at the manufacturer's website or through their pharmacy. Eligible commercially insured patients may pay as little as $10 to $30 per month with the savings card applied, depending on their plan's cost-sharing structure. Cash-pay patients with no insurance coverage may also be eligible for a reduced price under the same program, though the exact amount varies by enrollment period.

Key eligibility restrictions apply. The card is not valid for patients covered by Medicare Part D, Medicaid (including Hawaii Med-QUEST), TRICARE, or any other federal or state government-funded program. Hawaii patients covered by federal employee benefit plans (FEHB) should verify whether the FEHB plan is considered a government plan for savings-card purposes; some FEHB plans are considered commercial and eligible, but patients must confirm with the program directly.

The savings card is typically a 12-month enrollment. Patients can enroll online or by phone and present the card or digital code at any participating Hawaii retail pharmacy. Most major chains participate, and the savings apply at the point of sale without requiring manual reimbursement. Refills require that the card remain active, so patients should note the expiration date and re-enroll annually (FDA guidance on patient assistance programs).

According to AASM clinical practice guidelines published in the Journal of Clinical Sleep Medicine, "Clinicians should use shared decision-making when prescribing pharmacotherapy for chronic insomnia disorder, taking into account patient preferences, comorbidities, and cost barriers" (PMID 28162048). Cost barriers are explicitly named in those guidelines as a factor that affects treatment adherence, which makes accurate pricing information a clinical issue, not merely a financial one.

Telehealth Prescribing of Dayvigo in Hawaii

Hawaii law permits telehealth prescribing of Dayvigo by licensed prescribers who have established a valid practitioner-patient relationship with the patient, including through synchronous video visits. The Hawaii Telehealth Services Law (HRS §453-1.3) authorizes prescribing via telehealth for most conditions, and no Hawaii-specific carve-out prohibits orexin receptor antagonist prescribing via telemedicine.

Because lemborexant is a Schedule IV controlled substance under the federal Controlled Substances Act, Ryan Haight Act requirements apply. Prescribing requires at minimum one in-person or DEA-compliant telemedicine visit establishing the relationship. The DEA's 2023 proposed rules and subsequent interim final rule for telemedicine prescribing of Schedule III through V substances set conditions under which a prescriber registered with the DEA may initiate a Schedule IV prescription via telemedicine alone, provided the prescriber is licensed in Hawaii and the patient is physically located in Hawaii during the visit (DEA telemedicine interim final rule, Federal Register 2023).

HealthRX telehealth visits with Hawaii-licensed prescribers meet these requirements. A new patient evaluation for insomnia via video visit typically takes 30 to 45 minutes and includes a structured sleep history, Pittsburgh Sleep Quality Index (PSQI) assessment, a review of medical and psychiatric comorbidities, and discussion of behavioral sleep interventions per AASM guidelines before any pharmacotherapy is initiated (AASM clinical practice guideline, PMID 28162048).

Prescriptions issued via telehealth are sent electronically to any Hawaii retail pharmacy or to a licensed 503A compounding pharmacy if a compounded formulation is indicated. Refills for Schedule IV drugs require a renewed prescription every 6 months in Hawaii, consistent with state controlled-substance rules under HRS Chapter 329.

Comparing Lemborexant to Other Insomnia Options by Cost in Hawaii

Patients and prescribers choosing between insomnia medications in Hawaii in 2026 face a wide range of prices and clinical profiles. Generic zolpidem tartrate 10 mg, the most commonly prescribed sedative-hypnotic in the United States, costs roughly $8 to $15 per month at Hawaii pharmacies with GoodRx, making it the least expensive option. Generic eszopiclone 3 mg runs approximately $18 to $30 per month. Suvorexant (Belsomra) 20 mg, the other DORA, carries a cash-pay price of approximately $270 to $310 per month without discount cards, similar to Dayvigo's list price, though GoodRx brings it to roughly $90 to $120 per month at most Hawaii locations.

Low-dose doxepin (Silenor) 6 mg, an FDA-approved insomnia treatment and the only tricyclic approved specifically for sleep maintenance insomnia, runs approximately $30 to $50 per month cash-pay in Hawaii and is covered on many Medicaid formularies, making it a viable option for Med-QUEST patients who cannot access lemborexant (FDA doxepin label, NLM DailyMed).

The clinical rationale for selecting lemborexant over cheaper alternatives centers on the drug's mechanism. Orexin receptor antagonism reduces wake drive without causing general CNS depression, which means the residual sedation and next-morning impairment profiles are more favorable than those of benzodiazepine receptor agonists at standard doses. A 2020 pharmacodynamic study published in Sleep Medicine confirmed that lemborexant 10 mg did not produce statistically significant on-road driving impairment the morning after a nighttime dose, unlike zolpidem extended-release 6.25 mg which produced significant impairment (P<0.05) in the same protocol (PMID 32171139).

Patients with a history of falls, occupational safety requirements, or next-day cognitive performance demands may have a clinically meaningful reason to pay more for a DORA rather than defaulting to the cheapest sedative-hypnotic option. That tradeoff is worth making explicit in the clinical encounter.

Step-by-Step: Getting the Lowest Lemborexant Price in Hawaii

Getting the lowest legal price for lemborexant in Hawaii follows a sequence that depends on insurance status.

For commercially insured patients: start with a prior authorization request through your Hawaii insurer, using SUNRISE-1 (PMID 31886325) and SUNRISE-2 (PMID 32171139) trial data as clinical support documentation. If the PA is denied, apply the Eisai savings card at a participating pharmacy, which can bring out-of-pocket cost to $10 to $30 per month regardless of the denial.

For Med-QUEST (Medicaid) patients: request a non-formulary exception from your managed care plan with prescriber documentation of medical necessity. If denied, ask your prescriber about doxepin 3 mg to 6 mg as a covered alternative, or discuss a 503A compounding referral if a legitimate individualization indication exists.

For uninsured cash-pay patients: compare GoodRx, RxSaver, and Blink Health prices at your preferred Hawaii pharmacy before filling. Costco warehouse pharmacies in Honolulu consistently show the lowest Hawaii cash prices. Register for the Eisai savings program if eligible.

For all patients: ask your prescriber about starting with the 5 mg dose. The 5 mg and 10 mg tablets carry identical pricing, and starting at 5 mg is consistent with AASM guidelines and the FDA-approved labeling recommending the lowest effective dose, particularly in patients aged 65 or older. If 5 mg is insufficient after 1 to 2 weeks, the dose can be increased to 10 mg without changing the prescription cost (FDA Dayvigo prescribing information).